New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control
Recruiting now
This study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…
Phase: PHASE2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC